Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-20T21:55:36.478Z Has data issue: false hasContentIssue false
  • English
  • Français

Induced psychosis after withdrawal of varenicline: a case report

Published online by Cambridge University Press:  24 June 2014

María T. López Arteaga ,
Carlos Amo ,
Eva M. Sánchez Morla  and
Marina Sánchez Román
María T. López Arteaga*
Affiliation:
Department of Psychiatry, Hospital Universitario de Guadalajara, Guadalajara, Spain
Carlos Amo
Affiliation:
Department of Psychiatry, Hospital Universitario de Guadalajara, Guadalajara, Spain
Eva M. Sánchez Morla
Affiliation:
Department of Psychiatry, Hospital Universitario de Guadalajara, Guadalajara, Spain
Marina Sánchez Román
Affiliation:
Department of Psychiatry, Hospital Universitario de Guadalajara, Guadalajara, Spain
*
María Teresa López Arteaga, Department of Psychiatry, Hospital Universitario de Guadalajara, C/ Donante de sangre S/N, 19002 Guadalajara, Spain. Tel: +34 949 209 200; Fax: +34 949 209 218; E-mail: mariatelarteaga@gmail.com
Get access Rights & Permissions [Opens in a new window]

Extract

López Arteaga MT, Amo C, Sánchez Morla EM, Sánchez Román M. Induced psychosis after withdrawal of varenicline: a case report.

Objective: Varenicline has been associated with psychiatric side effects, and cases with psychotic symptoms during treatment have been reported, few of them after the withdrawal. We describe a case with no current or previous medical or psychiatric history.

Method: A single case report.

Results: The patient without previous psychiatric pathology, following the withdrawal of treatment with varenicline, experiences delirium and behavioural disturbances. There was a remission of symptoms after 3 weeks of treatment with risperidone.

Conclusion: Discontinuation of treatment with varenicline due to poor tolerance for side effects (nausea and insomnia) could trigger psychotic symptoms in subjects with no personal or family psychiatric history.

Keywords

psychosisvareniclinewithdrawal symptoms
Type
Case Reports
Information
Acta Neuropsychiatrica , Volume 23 , Issue 5 , October 2011 , pp. 252 - 255
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hays, JT, Ebbert, J, Sood, A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008;121:532–542. CrossRefGoogle ScholarPubMed
2. Oncken, C, Gonzales, D, Nides, M et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571–1577. CrossRefGoogle ScholarPubMed
3. Foulds, J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006;60:571–576. CrossRefGoogle ScholarPubMed
4. US Food and Drug Administration. MedWatch, 2007. URL http://www.fda.gov/medwatch/safety/2007/safety07.htmChantix [accessed on 30 September 2010].Google Scholar
5. Freedman, R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164:1269. CrossRefGoogle ScholarPubMed
6. Kohen, I, Kremen, N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269–1270. CrossRefGoogle Scholar
7. Pumariega, AJ, Nelson, R, Rotenberg, L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008;13:511–514. CrossRefGoogle Scholar
8. Morstad, A, Kutscher, E, Kennedy, W, Carnahan, R. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008;42:288–289. CrossRefGoogle ScholarPubMed
9. Raidoo, BM, Kutscher, EC. Visual hallucinations associated with varenicline: a case report. J Med Case Reports 2009;3:7560. CrossRefGoogle ScholarPubMed
10. Alhatem, F, Black, JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol 2009;32:117–118. CrossRefGoogle Scholar
11. Liu, ME, Tsai, SJ, Yang, ST. Varenicline-induced mixed mood and psychotic episode in a patient with Schizoaffective Disorder. CNS Spectr 2009;14:346. CrossRefGoogle Scholar
12. Laine, P, Marttila, J, Lindeman, S. Hallucinations in the context of varenicline withdrawal. Am J Psychiatry 2009;166:619–620. CrossRefGoogle ScholarPubMed
13. DiPaula, BA, Thomas, MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy 2009;29:852–857. CrossRefGoogle Scholar
14. May, AC, Rose, D. Varenicline withdrawal-induced delirium with psychosis. Am J Psychiatry 2010;167:720–721. CrossRefGoogle ScholarPubMed
15. Cinemre, B, Akdag, ST, Metin, O, Doganavsargil, O. Varenicline-induced psychosis. CNS Spectr 2010;15:470–472. Google ScholarPubMed
16. Levander, S, Eberhard, J, Lindström, E. Nicotine use and its correlates in patients with psychosis. Acta Psychiatr Scand 2007;116(Suppl. 435):27–32. CrossRefGoogle Scholar
17. Fatemi, SH. Vareniclline efficacy and tolerability in a subject with schizophrenia. Schizophr Res 2008;103:328–329. CrossRefGoogle Scholar
18. Evins, AE, Goff, DC. Vanericline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry 2008;69:1016. CrossRefGoogle ScholarPubMed
19. Anghelescu, I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci 2009;21:102–103. CrossRefGoogle Scholar
20. Rollema, H, Coe, JW, Chambers, LK, Hurst, RS, Stahl, SM, Williams, KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316–325. CrossRefGoogle ScholarPubMed
21. Janowsky, DS, Overstreet, DH. Acetylcholine and mood disorders. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: the fourth generation of progress bloom. New York: Raven Press, 1995: 946. Google Scholar